Vasopharm

company

About

Vasopharm is focused on the R&D of novel therapeutics for the treatment of cerebro and cardiovascular diseases and their symptoms.

  • 1 - 10

Details

Last Funding Type
Private Equity(PE)
Last Funding Money Raised
€9.50M
Industries
Biotechnology,Medical,Therapeutics
Founded date
Jul 1, 1998
Number Of Employee
1 - 10
Operating Status
Active

vasopharm is a biopharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases and their consequences. In this area, the company is focused on the development of therapeutics influencing the bioavailability of nitric oxide (NO), a cellular signalling molecule involved in many physiological and pathological processes. vasopharm’s drug candidate VAS203 is an allosteric NO synthase inhibitor and represents a completely new class of modulators of nitric oxide synthase (NOS) enzymes. It rapidly lowers excessive NO production in cerebral vessels and tissues, thereby preventing life-threatening increases in intracranial pressure and associated inflammatory processes following traumatic brain injury.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
4
€29.50M $18.30M
Vasopharm has raised a total of €29.50M $18.30M in funding over 2 rounds. Their latest funding was raised on Jul 11, 2019 from a Private Equity(PE) round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jul 11, 2019 Private Equity(PE) €9.50M 3 EF Investments Detail
Jan 21, 2016 Series G €20M 1 Detail
Jun 24, 2013 Series F $6.50M 1 Detail
Jan 30, 2006 Series B $11.80M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
3
Vasopharm is funded by 3 investors. EF Investments and Future Capital Development Fund are the most recent investors.
Investor Name Lead Investor Funding Round
EF Investments Yes Private Equity(PE)
Future Capital Development Fund Private Equity(PE)
Bayern Kapital Private Equity(PE)